Par Drugs and Chemicals Past Earnings Performance
Past criteria checks 5/6
Par Drugs and Chemicals has been growing earnings at an average annual rate of 21.2%, while the Pharmaceuticals industry saw earnings growing at 13.6% annually. Revenues have been growing at an average rate of 15.2% per year. Par Drugs and Chemicals's return on equity is 18.9%, and it has net margins of 17.6%.
Key information
21.2%
Earnings growth rate
21.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 15.2% |
| Return on equity | 18.9% |
| Net Margin | 17.6% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Earnings Working Against Par Drugs and Chemicals Limited's (NSE:PAR) Share Price Following 26% Dive
Dec 20
There's No Escaping Par Drugs and Chemicals Limited's (NSE:PAR) Muted Earnings Despite A 26% Share Price Rise
Oct 29Improved Earnings Required Before Par Drugs and Chemicals Limited (NSE:PAR) Stock's 29% Jump Looks Justified
Apr 16Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today
Apr 05Do Par Drugs and Chemicals' (NSE:PAR) Earnings Warrant Your Attention?
Nov 03If EPS Growth Is Important To You, Par Drugs and Chemicals (NSE:PAR) Presents An Opportunity
May 19Does Par Drugs and Chemicals (NSE:PAR) Deserve A Spot On Your Watchlist?
Mar 17Do Par Drugs and Chemicals's (NSE:PAR) Earnings Warrant Your Attention?
Oct 22Investors Shouldn't Be Too Comfortable With Par Drugs and Chemicals' (NSE:PAR) Robust Earnings
Aug 11Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Is Well Worth Watching
Jul 14Is Par Drugs and Chemicals Limited (NSE:PAR) An Attractive Dividend Stock?
Mar 31Are Strong Financial Prospects The Force That Is Driving The Momentum In Par Drugs and Chemicals Limited's NSE:PAR) Stock?
Mar 05Chairman of the Board & MD Falgun Savani Just Bought A Handful Of Shares In Par Drugs and Chemicals Limited (NSE:PAR)
Feb 06
Here's Why I Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today
Jan 10How Does Par Drugs and Chemicals Limited (NSE:PAR) Fare As A Dividend Stock?
Dec 13Revenue & Expenses Breakdown
How Par Drugs and Chemicals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,041 | 183 | 58 | 0 |
| 30 Jun 24 | 953 | 146 | 56 | 0 |
| 31 Mar 24 | 956 | 145 | 55 | 0 |
| 31 Dec 23 | 973 | 142 | 53 | 0 |
| 30 Sep 23 | 962 | 127 | 52 | 0 |
| 30 Jun 23 | 952 | 115 | 51 | 0 |
| 31 Mar 23 | 957 | 113 | 49 | 0 |
| 31 Dec 22 | 933 | 103 | 46 | 0 |
| 30 Sep 22 | 873 | 106 | 42 | 0 |
| 30 Jun 22 | 821 | 91 | 42 | 0 |
| 31 Mar 22 | 751 | 92 | 41 | 0 |
| 31 Dec 21 | 692 | 112 | 41 | 0 |
| 30 Sep 21 | 686 | 112 | 41 | 0 |
| 30 Jun 21 | 631 | 115 | 40 | 0 |
| 31 Mar 21 | 608 | 116 | 40 | 0 |
| 31 Dec 20 | 579 | 88 | 38 | 0 |
| 30 Sep 20 | 550 | 83 | 38 | 0 |
| 30 Jun 20 | 554 | 65 | 40 | 0 |
| 31 Mar 20 | 558 | 48 | 41 | 0 |
| 31 Dec 19 | 532 | 41 | 38 | 0 |
| 30 Sep 19 | 506 | 20 | 36 | 0 |
| 30 Jun 19 | 484 | 23 | 36 | 0 |
| 31 Mar 19 | 463 | 25 | 36 | 0 |
| 31 Mar 18 | 424 | 15 | 35 | 0 |
| 31 Mar 17 | 488 | 18 | 33 | 0 |
| 31 Mar 16 | 333 | 4 | 22 | 0 |
Quality Earnings: PAR has high quality earnings.
Growing Profit Margin: PAR's current net profit margins (17.6%) are higher than last year (13.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PAR's earnings have grown significantly by 21.2% per year over the past 5 years.
Accelerating Growth: PAR's earnings growth over the past year (44.2%) exceeds its 5-year average (21.2% per year).
Earnings vs Industry: PAR earnings growth over the past year (44.2%) exceeded the Pharmaceuticals industry 20.6%.
Return on Equity
High ROE: PAR's Return on Equity (18.9%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/21 05:39 |
| End of Day Share Price | 2025/01/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Par Drugs and Chemicals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|